was borne out of national priority, on May 21, 2000 to ensure availability of effective, safe and affordable Liposomal Amphotericin B. On November 13, 2000 it was incorporated as a medical biotechnology company engaged in research, development, manufacturing and marketing of healthcare products. To address to the unmet medical needs, the company is focused on new age formulations particularly controlled release pharmaceuticals employing an array of technologies of novel drug delivery systems (NDDS).